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Michael D. Ezekowitz, MB, ChB, DPhil; Daniel E. Singer, MD; Laine Thomas, PhD; Eric D. Peterson, MD, MPH; Elaine M. Hylek, MD, MPH;
on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients
Background-—Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial ﬁbrillation. Adoption patterns of
this new agent in community practice are unknown.
Methods and Results-—We studiedpatterns of dabigatran useamong patients enrolled in theOutcomes Registry for Better Informed
TreatmentofAtrialFibrillation(ORBIT-AF)RegistrybetweenJune2010andAugust2011andfollowedfor12 months.Among9974atrial
ﬁbrillation patients included, 1217 (12%) were treated with dabigatran during the study. Overall, patients receiving dabigatran were
younger (median age 72 versus 75 years, P<0.0001), more likely to be white (92% versus 89%, P=0.005), more likely to have private
insurance(33%versus25%,P<0.0001),andlesslikelytohavepriorcardiovasculardisease(4%versus33%,P<0.0001).They hadmore
new-onset atrial ﬁbrillation (8.8% versus 4.1%, P<0.0001), lower CHADS2 scores (estimated risk based on the presence of congestive
heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack; mean 2.0 versus 2.3,
P<0.0001), and lower Anticoagulation and Risk Factors in Atrial Fibrillation scores (mean 2.4 versus 2.8, P<0.0001). More than half
(n=14/25, 56%) ofpatients withsevere kidneydisease werenotprescribedreduced dosing, whereas10%(n=91/920) with preserved
renalfunctionreceivedlowerdosing.Amongpatientsnotondabigatranatbaseline,8%haddabigatraninitiatedduringfollow-up.Patient
educationwassigniﬁcantlyassociatedwithswitchingfromwarfarintodabigatran(adjustedoddsratioforpostgraduate1.73,P=0.007),
whereas antiarrhythmic drug use signiﬁcantly correlated with de novo adoption of dabigatran (adjusted odds ratio 2.4, P<0.0001).
Conclusions-—Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding. Patients appeared to drive
switching from warfarin, whereas clinical characteristics inﬂuenced de novo start of dabigatran. These data suggest cautious early
uptake of dabigatran, and more careful attention to dosing adjustments is warranted.
Clinical Trial Registration-—URL: Clinicaltrials.gov. Unique identiﬁer: NCT01165710. (J Am Heart Assoc. 2013;2:e000535 doi:
10.1161/JAHA.113.000535)
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A
trial ﬁbrillation (AF) increases the risk of stroke or
systemic embolism in patients by up to 5-fold.
1 Tradi-
tional therapy with vitamin K antagonism (ie, warfarin) has
reduced that risk to 1% annually, depending on the
population treated.
2 However, warfarin has signiﬁcant short-
comings, particularly its narrow therapeutic window, need for
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ORIGINAL RESEARCHfrequent monitoring, and numerous drug and food interac-
tions. Alternatives to warfarin have been a long-sought goal in
the clinical care of patients with AF. The Randomized
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
demonstrated that a novel direct thrombin inhibitor, dabiga-
tran etexilate, could reduce risks of ischemic and overall
strokes while having no higher risk of bleeding relative to
warfarin.
3 Based on these data, dabigatran became the ﬁrst
alternative, novel oral anticoagulant (OAC) approved for
thromboembolism prevention in nonvalvular AF.
3,4
Manyhadpredictedthattheuptakeofthisalternativewould
be very rapid, given that it lacked many of warfarin’s pitfalls.
Patients no longer required routine monitoring, dietary intake
did not alter anticoagulant effect, and dose adjustments
were not required on a routine basis (eg, during temporary
antibiotic therapy). However, there is limited knowledge
regarding the uptake patterns of dabigatran for AF in contem-
porary US practice and available data are limited to physician
surveys or administrative claims.
5,6 It is not clear what
proportion of patients with AF in the United States is treated
with dabigatran and what drives selection of such patients.
Last, dosing of dabigatran presented a challenge for regulatory
authorities,
4,7 and it is not clear how providers responded in
routine practice, particularly for older patients and/or those
with renal insufﬁciency. The objectives of the current analysis
were to (1) describe early patterns of dabigatran use in
community practice, (2) identify patient and/or provider
factors associated with the use of dabigatran in patients
with AF, and (3) describe dosing patterns of dabigatran.
Methods
The Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF) is a nationwide registry of outpatients
with AF treated by primary care physicians, cardiologists,
and/or electrophysiologists. Sites were invited to participate
based on achieving a nationally representative sample,
through an adaptive design geared toward heterogeneity of
practice-type and geography. Site management and study
coordination were performed by the Duke Clinical Research
Institute. Each site enrolled consecutive patients, aged
≥18 years, with electrocardiographically documented AF that
was not due to a reversible cause. They were expected to
provide follow-up every 6 months for ≥2 years and could not
be included if life expectancy was <6 months. A web-based
case report form was used to gather data, primarily from the
patient’s medical record and treating physician. Data compo-
nents included demographics, medical history, AF history
(including symptoms), medical therapies, vital signs, labora-
tory and echocardiographic measures, and incident proce-
dures and adverse events. Additional details of the ORBIT-AF
design and rationale have been previously described.
8
The ORBIT-AF Registry began before the availability of any
novel OACs (June 2010), however, dabigatran was approved
shortly thereafter (October 2010).
9 The registry completed
enrollment before approval of any other novel anticoagulants,
and rivaroxaban and apixaban were subsequently approved
during the follow-up phase (Figure 1).
Collection of data on medical therapies included
historical anticoagulation use, current anticoagulants, dosing,
monitoring of international normalized ratios (INRs, where
appropriate), and reasons for any discontinuations or contra-
indications. Warfarin monitoring (INR) was reported through-
out follow-up and was requested at baseline (but subject to
availability at enrollment). Dosing for dabigatran is recorded as
total daily dosing, and sites are prompted to conﬁrm each
entry of anticoagulant dosing to ensure appropriate dose
reporting. Individual twice-daily dosing levels were calculated
from the total daily dose. Sites were instructed to record the
present medical therapy, as well as the reasons for any
discontinuations in therapies, every 6 months. The present
analysis includes patient follow-up to 1 year.
Study Population
The overall study population included all patients in the
registry who had ≥1 visit (baseline or follow-up) on or after the
ﬁrst reported use of dabigatran in the registry and thus were
eligible for treatment with dabigatran. First, we assessed
temporal uptake of dabigatran chronologically. Next, patients
who were treated with dabigatran during the study period
were compared with patients who did not receive dabigatran.
Additionally, we described dabigatran dosing patterns overall
and by age and renal function.
Patients Adopting Dabigatran During Follow-up
To identify speciﬁc factors associated with the initiation of
dabigatran, the population of dabigatran users was subse-
Figure 1. Timeline of ORBIT-AF enrollment vs emergence of novel
oral anticoagulants in the US. ORBIT-AF indicates Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation.
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warfarin at baseline and (2) patients without OAC at baseline
(antiplatelet agents may have been used). To assess baseline
and follow-up characteristics that may have inﬂuenced
dabigatran adoption, we purposefully did not include patients
already taking dabigatran at baseline (n=501; no other OACs
were used at baseline). Patients without follow-up visits at 6
or 12 months (n=670) and those missing data on dabigatran
at follow-up (n=9) were also excluded (Figure 2). Each of
these groups was queried for rates of dabigatran use at
subsequent follow-up (6 or 12 months), and comparison was
made between patients who did not adopt dabigatran and
those who did. Multivariable models were used to identify
factors associated with dabigatran adoption at follow-up.
Statistical Methods
All baseline characteristics and univariate data are presented
as frequencies and percentages for categorical variables and
medians (IQR) or means (SD) for continuous variables. The
baseline characteristics were compared using the v
2 for
categorical variables and the Wilcoxon rank sum test for
continuous variables.
We identiﬁed factors associated with initiating dabigatran
in 2 distinct populations: (1) those taking warfarin at baseline
(switched to dabigatran versus those not) and (2) those
without OACs at baseline (started dabigatran versus those
not). Dabigatran use was captured in discrete time intervals at
6 and 12 months, rather than speciﬁc dates. We therefore
used a proportional odds model for discrete time to identify
factors related to starting dabigatran at either time interval.
This method essentially ﬁt a logistic regression model for the
binary occurrence of event, at each discrete time point, and
combined the results to provide a single odds ratio (OR) for
the effect of covariates. The method can also be viewed as a
discrete time Cox model for time-to-starting dabigatran. As
with time-to-event analyses, individuals contributed all avail-
able follow-up information and were censored (removed from
the risk set) when the patient was lost to follow-up. Thus,
these models included patients with ≥1 follow-up visit but not
necessarily full follow-up.
10,11
Candidate variables included demographics, medical his-
tory, vital signs, laboratory data, AF status, pharmacotherapy,
contraindication to OAC, functional status, and provider
specialty. All continuous variables were evaluated for nonlin-
earity with the outcome, and nonlinear relationships were
addressed using linear splines.
Missing data were multiply imputed, and ﬁnal estimates
and standard errors reﬂect the combined analysis over 5
imputed datasets (missingness was <5% for all the candidate
variables except serum creatinine [7%], hematocrit [11%], and
left ventricular ejection fraction [11%]). Model selection using
backward selection with a stay criterion of 0.05 using the ﬁrst
imputed dataset was used to obtain a model in which each
factor was independently associated with switching to
dabigatran within 1 year. The model was ﬁt using logistic
generalized estimating equations with exchangeable working
correlation matrix to account for within-site clustering
because patients at the same site are more likely to have
similar responses relative to patients at other sites (ie, within-
center correlation for responses). We used empirical standard
errors, robust to mis-speciﬁcation of the correlation structure.
Backward selection with an inclusion criterion of 0.05 was
used to build the models. Adjusted associations for outcomes
were displayed as ORs with 95% CIs.
Two separate sensitivity analyses were performed. In the
ﬁrst, the time-in-therapeutic range (TTR) of baseline INR data
was calculated using a modiﬁcation of the Rosendaal
method
12 and was included as a predictor in the multivariable
model for switching to dabigatran (among patients receiving
warfarin at baseline). We imputed daily INR values between
the ﬁrst and last measured INR among INR values obtained
before baseline. This analysis was performed only for patients
receiving warfarin for ≥60 days before baseline, with ≥2 INR
values measured before baseline. Overall, 5315 patients (89%
of those on warfarin at baseline for ≥60 days) had ≥2 INR
values available at baseline and TTR was calculated using
these values. For the remaining 11%, TTR was imputed using
multiple imputation for the sensitivity analysis. The second
sensitivity analysis was performed to evaluate the con-
tribution of post baseline events into the models for switching.
In both patient populations (warfarin and no OAC at base-
line), separate, time-dependent covariates for cause-speciﬁc
Figure 2. Patient inclusion and exclusion in the current analysis.
ORBIT-AF indicates Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation.
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switching to dabigatran. Cause-speciﬁc events were classiﬁed
by the investigator and included cardiovascular, bleeding, or
noncardiovascular, nonbleeding and hospitalization. If a
cardiovascular event occurred before 6 months, the time-
dependent covariate would take a value of 1 at both the 6-
month and 12-month intervals. To the extent that events
preceded switching, these associations are predictive. It is
also possible that switching preceded events but was not
measured until a later interval.
All analyses of the aggregate, deidentiﬁed data were
performed at the Duke Clinical Research Institute using SAS
software (version 9.3, SAS Institute).
Results
The overall ORBIT-AF population included 10 132 patients
from 176 sites from June 29, 2010, through August 9, 2011
(Figure 2). Dabigatran use was ﬁrst reported in the registry on
November 23, 2010. After excluding 158 patients who were
not observed after that date, there was a study population of
9974 patients from 176 sites. Of these, 1217 (12%) were
treated with dabigatran during the study period. Temporal use
of dabigatran is shown in Figure 3.
Figure 3. Temporal adoption of dabigatran in ORBIT-AF. OAC
indicates oral anticoagulation; ORBIT-AF, Outcomes Registry for
Better Informed Treatment of Atrial Fibrillation.
Table 1. Demographics, Past Medical History, and Laboratory Studies of Study Population
Total (N=9974) Dabigatran Treatment (n=1217) No Dabigatran Treatment (n=8757) P Value
Age, y 75 (67 to 82) 72 (64 to 80) 75 (67 to 82) <0.0001*
Female sex 42 41 43 0.3
Race
White 89 92 89 0.005
Black or African American 4.9 3.5 5.1
Hispanic 4.3 2.9 4.4
Other 1.4 1.6 1.4
Health insurance status
Medicare or Medicaid 70 63 71 <0.0001*
Private 26 33 25
Other 4.9 4.7 4.9
Hypertension 83 82 83 0.6
Hyperlipidemia 72 70 72 0.1
Diabetes 29 26 30 0.004*
COPD 16 13 17 0.002*
Osteoporosis 13 12 13 0.1
Prior gastrointestinal bleeding 9.0 7.2 9.3 0.02*
Cognitive impairment or dementia 3.1 3.1 3.1 0.9
Frailty 5.7 3.5 6.0 0.0005*
BMI, kg/m
2 29 (25 to 34) 30 (26 to 35) 29 (25 to 34) <0.0001*
Hemoglobin, g/dL 13.5 (12.3 to 14.6) 13.7 (12.6 to 14.9) 13.5 (12.2 to 14.6) <0.0001*
Calculated creatinine clearance*, mL/min per 1.73 m
2 70 (50 to 97) 78 (57 to 105) 69 (49 to 95) <0.0001*
Values are presented as % or median (interquartile range), unless noted otherwise. BMI indicates body mass index; COPD, chronic obstructive pulmonary disease.
*As calculated by the Cockcroft-Gault formula.
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72 versus 75 years, P<0.0001), more likely to be white (92%
versus 89%, P=0.005), more likely to have private insurance
(33% versus 25%, P<0.0001), and had higher calculated
creatinine clearance (CrCl, median 78 versus 69 mL/min per
1.73 m
2, P<0.0001) compared with patients who did not
receive dabigatran (Table 1).
Those receiving dabigatran were less likely to have any
form of cardiovascular disease (Table 2), including peripheral
vascular disease (11% versus 14%, P=0.002), coronary artery
disease (24% versus 33%, P<0.0001), and cerebrovascular
disease (13% versus 16%, P=0.001). Left ventricular ejection
fraction was higher in patients treated with dabigatran
(median 58% versus 55, P<0.0001).
Historical AF data and anticoagulation history are pre-
sented in Table 3. Compared with patients not treated with
dabigatran, those receiving dabigatran were more likely to
have new-onset AF at baseline (8.8% versus 4.1%) and had
lower CHADS2 scores (estimated risk based on the presence
of congestive heart failure, hypertension, aged ≥75 years,
diabetes mellitus, and prior stroke or transient ischemic
attack; mean 2.0 versus 2.3, P<0.0001) and Anticoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) scores (mean 2.4
versus 2.8, P<0.0001). They were more likely to be managed
with a rhythm control strategy (38% versus 31%, P<0.0001),
including prior cardioversion (35% versus 29%, P<0.0001),
prior antiarrhythmic therapy (50% versus 45%, P=0.0001), and
prior catheter ablation for AF (8.7% versus 5.1%, P<0.0001).
Management by an electrophysiology provider was slightly
more common in patients receiving dabigatran (19% versus
17%, P=0.03).
Dabigatran Dosing
Dosing strategies of dabigatran, stratiﬁed by age and CrCl,
13
are shown in Figure 4. The use of 150 mg twice daily was the
prevailing dosing strategy, across subgroups, except in
patients with CrCl 15 to 30 mL/min per 1.73 m
2 (56%
Table 2. Cardiovascular History
Total (N=9974) Dabigatran Treatment (n=1217) No Dabigatran Treatment (n=8757) P Value
Peripheral vascular disease 13 11 14 0.002
Coronary artery disease 32 24 33 <0.0001
Prior MI 16 10 17 <0.0001
Prior CABG 15 10 15 <0.0001
Prior PCI 17 13 18 <0.0001
Heart failure 32 25 33 <0.0001
Implanted cardiac device 27 20 28 <0.0001
Significant valve disease 25 18 26 <0.0001
Moderate/severe mitral stenosis 1.4 0.6 1.5 0.009
Prior valve replacement 8.1 3.2 8.8 <0.0001
Mechanical valve 3.1 0.5 3.5 <0.0001
Prior cerebrovascular events 16 13 16 0.001
Stroke (all-cause) 8.8 6.7 9.1 0.005
Stroke—nonhemorrhagic 7.9 6.0 8.2 0.009
Stroke—hemorrhagic 0.8 0.6 0.8 0.4
Other intracranial bleeding 0.9 1.0 0.9 0.8
TIA 8.1 6.9 8.2 0.1
Cardiac medications
b-Blocker 64 62 64 0.10
Nondihydropyridine calcium channel blocker 17 18 16 0.3
ACEI or ARB 51 52 51 0.6
Statin 55 54 55 0.4
LVEF, % 55 (50 to 61) 58 (52 to 65) 55 (50 to 60) <0.0001
LA diameter, cm 4.4 (3.9 to 5.0) 4.4 (3.9 to 4.9) 4.4 (3.9 to 5.0) 0.0498
Values are presented as % or median (IQR). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft surgery; LA,
left atrium; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
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with CrCl >30 mL/min per 1.73 m
2 (n=256), 14% were
prescribed 75 mg twice daily. Ten percent of patients under
the age of 80, with preserved renal function, were prescribed
75 mg twice daily. P-glycoprotein inhibitors were used in a
minority of these patients with preserved renal function
receiving the lower dabigatran dose (10.8% received drone-
darone, 17% received nondihydropyridine calcium channel
blockers, 6.7% received amiodarone, and 0.8% received
quinidine).
Adoption of Dabigatran During Follow-up
Among 6654 patients receiving warfarin at baseline, 532
(8.0%) were switched to dabigatran at 6- or 12-month follow-
up. As described by the site investigator, major reasons for
Table 3. Atrial Fibrillation and Anticoagulation History
Total (N=9974) Dabigatran Treatment (n=1217) No Dabigatran Treatment (n=8757) P Value
AF type at baseline
New onset 4.7 8.8 4.1 <0.0001*
Paroxysmal 51 49 51
Persistent 17 18 17
Longstanding persistent 28 23 29
Time from AF diagnosis >12 mo 81 70 83 <0.0001*
Rhythm control treatment strategy reported 32 38 31 <0.0001*
CHADS2 score, mean (SD) 2.3 (1.3) 2.0 (1.2) 2.3 (1.3) <0.0001*
CHADS2 score groups
0 6.6 7.6 6.4 <0.0001*
12 2 3 0 2 1
≥27 1 6 2 7 2
ATRIA score, mean (SD) 2.8 (2.0) 2.4 (1.8) 2.8 (2.0) <0.0001*
Prior cardioversion 30 35 29 <0.0001*
Prior catheter ablation for AF 5.5 8.7 5.1 <0.0001*
Prior antiarrhythmic therapy 45 50 45 0.0001*
Current antiarrhythmic therapy 29 36 28 <0.0001*
Amiodarone 10.0 9.5 10.0 0.5
Sotalol 6.1 8.1 5.9 0.002*
Dronedarone 4.6 7.6 4.2 <0.0001*
Flecainide 2.9 4.0 2.8 0.02*
Propafenone 2.4 2.7 2.3 0.4
Dofetilide 1.9 2.6 1.8 0.08
Baseline antiplatelet therapy
Aspirin 44 39 45 0.0002*
Clopidogrel 7.0 4.2 7.4 <0.0001*
Anticoagulation clinic management at baseline 43 36 44 0.0003*
Relative or absolute contraindication to anticoagulation 13 11 13 0.049*
Treating provider specialty*
Primary care provider 67 65 68 0.06
Cardiologist 80 81 80 0.4
Electrophysiologist 17 19 17 0.03*
Neurologist 2.1 1.5 2.2 0.1
Values are presented as% or median (IQR), unless noted otherwise. AF indicates atrial ﬁbrillation; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CHADS2, estimated risk
based on the presence of congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack.
*Provider specialty is not mutually exclusive; each patient may have ≥1 specialists involved in the care of AF patients.
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(reasons are not mutually exclusive) physician preference
(n=213, 40%), patient preference (n=171, 32%), inability to
adhere to and/or monitor warfarin (n=32, 6.0%), high bleeding
risk (n=10, 1.9%), incident bleeding event (n=4, 0.8%), and
“other” (n=96, 18%). Warfarin discontinuation reason was not
available for 182 (34%) of patients. Of 2140 patients not
receiving OAC at baseline, 184 (8.6%) adopted dabigatran at
follow-up. Demographics (Table 4), cardiovascular history
(Table 5), and AF history (Table 6) are shown for patients
who did and those who did not adopt dabigatran during
follow-up.
Multivariable models of factors associated with adoption of
dabigatran during follow-up are shown in Figure 5. They
differed for patients receiving warfarin at baseline versus
those receiving no OAC at baseline. In patients receiving
warfarin, advanced education (adjusted OR for postgraduate
1.73, 95% CI 1.16 to 2.57, P=0.007) and cognitive impairment
(adjusted OR 1.92, 95% CI 1.20 to 3.07, P=0.007) were
associated with adoption of dabigatran. Among patients not
receiving OAC at baseline, current antiarrhythmic use
(adjusted OR 2.37, 95% CI 1.69 to 3.33, P<0.0001) was
signiﬁcantly associated with dabigatran initiation.
Sensitivity Analyses
In patients receiving warfarin at baseline, median TTR at
baseline among patients switched to dabigatran was 55% (IQR
38 to 73) versus 60% among patients not switched (IQR 42 to
75). Addition of TTR at baseline contributed minimally to the
overall model (c-index from 0.65 to 0.66, adjusted OR for
dabigatran adoption per 5% increase in TTR=0.99, 95% CI 0.97
to 1.01, P=0.2). Addition of interim cause-speciﬁc hospital-
ization during follow-up (as deﬁned by the site investigator) to
patients receiving warfarin at baseline model also contributed
minimally to model discrimination (c-index from 0.65 to 0.66).
Interim cardiovascular hospitalization (adjusted OR 1.32, 95%
CI 1.04 to 1.68, P=0.02) and noncardiovascular, nonbleeding
hospitalization (adjusted OR 1.42, 95% CI 1.09 to 1.85,
P=0.01) were both signiﬁcantly associated with dabigatran
adoption, whereas bleeding hospitalization did not have a
signiﬁcant association (adjusted OR 0.84, 95% CI 0.41 to
1.73, P=0.6).
In patients not receiving OAC at baseline, addition of
interim hospitalization data modestly improved the discrim-
inatory power of the model (c-index from 0.71 to 0.73).
Cardiovascular hospitalization (adjusted OR 2.72, 95% CI 1.89
to 3.93, P<0.0001) was signiﬁcantly associated with dabig-
atran adoption, but bleeding (adjusted OR 1.09, 95% CI 0.3 to
5.65, P=0.9) or noncardiovascular, nonbleeding (adjusted OR
1.31, 95% CI 0.78 to 2.2, P=0.3) hospitalizations were not.
Discussion
The development of dabigatran heralded a new era in the use
of OACs, and this analysis is among the ﬁrst to provide the
details of its uptake in the clinical care of US patients with AF.
Use of dabigatran was modest in this population (12% overall)
and appeared to plateau in late 2012. Patients receiving
dabigatran were generally younger, more likely to have private
health insurance, and less likely to have comorbid cardiovas-
cular disease. A signiﬁcant proportion (56%) of patients with
severe kidney disease did not receive adjusted-dose dabiga-
tran, whereas 10% of patients with normal renal function
received reduced dosing.
An alternative to warfarin has been a long-sought goal and
highly anticipated therapeutic option. yet a minority of
patients in clinical practice received dabigatran during the
study period. Furthermore, despite robust data demonstrating
lower rates of stroke in patients receiving dabigatran
compared with those receiving warfarin,
3 patients treated
with dabigatran in our study were at lower risk of stroke,
according to CHADS2 scores. They were also at lower risk of
bleeding, as represented by prior gastrointestinal bleeding
rates and ATRIA bleeding score. These data suggest a
conservative adoption strategy by many providers, transition-
ing patients to dabigatran who are least likely to experience
an adverse event. It is possible that physicians were
inﬂuenced by early case reports of fatal bleeding, coupled
with the caveat in the package insert of increased nonintra-
cranial bleeding among individuals aged ≥75 years, compared
with warfarin. As more methodologically rigorous data have
Figure 4. Distribution of dabigatran dosing overall and in high-risk
subgroups. Numbers may not sum to 100% due to reporting of other
dosing regimens. *Excludes patients with CrCl <30 mL/min per
1.73 m
2. CrCl indicates creatinine clearance calculated by the
Cockcroft-Gault formula.
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14 the rates of dabigatran use may increase. It is
noteworthy that patient preference triggered the switch from
warfarin for one-third of the patients, reinforcing the impor-
tance of patient engagement in treatment decisions. This is
also evidenced in the multivariable analysis, demonstrating
patient-related characteristics, such as education level and
age, closely related to the switch from warfarin to dabigatran.
In contrast, characteristics of AF disease (eg, AF persistence,
antiarrhythmic use) more closely correlated with de novo
initiation of dabigatran.
Our data might seem to contrast those from Kirley et al,
who used broad US administrative claims data to show a
signiﬁcant increase in use of dabigatran, for both AF and other
indications.
6 They demonstrated an overall increase in
dabigatran treatment from 3% to 19% of anticoagulation
visits, but they also noted that in the last period of follow-up
(late 2011), only 63% of these dabigatran prescriptions were
for AF. Furthermore, it is not clear what proportion of those
patients had new or recent diagnoses of AF (a minority of our
cohort). Our cohort more speciﬁcally addresses the question
of implementing dabigatran in a population of AF patients with
a previously established care plan for the prevention of
thromboembolism. While some providers advocate uniformly
transitioning patients from warfarin to new anticoagulants,
others are more hesitant and the prevailing strategy had been
unclear. These results from ORBIT-AF demonstrate that most
providers and patients have not been aggressive about
adopting this new therapy but seem to reserve it for speciﬁc
situations.
The appropriate level of penetrance for dabigatran use in
AF patients is not clear. The early selection of lower-risk
younger patients for this breakthrough therapy may reﬂect
physician reaction to isolated case reports of serious
hemorrhage and concerns regarding prescription of the
Table 4. Demographics, Past Medical History, and Laboratory Studies
Use of Warfarin at Baseline No OAC at Baseline
Not Switched to
Dabigatran (n=6122)
Switched to
Dabigatran (n=532) P Value
Not Switched to
Dabigatran (n=1956)
Switched to
Dabigatran (n=184) P Value
Age, y 76 (68 to 82) 73 (64 to 80) <0.0001 74 (64 to 82) 68 (62 to 80) 0.005
Female 43 41 0.4 43 41 0.5
Race
White 89 94 0.002 89 90 0.9
Black or African American 4.7 2.8 5.1 4.4
Hispanic 4.5 1.7 3.6 3.8
Other 1.3 1.9 1.7 1.1
Health insurance status
Medicare or Medicaid 73 66 0.001 65 55 0.01
Private 22 29 30 40
Other 4.5 5.1 5.3 4.9
Hypertension 85 84 0.4 78 79 0.7
Hyperlipidemia 74 72 0.3 69 65 0.3
Diabetes 31 24 0.002 26 25 0.8
COPD 17 14 0.1 17 13 0.2
Osteoporosis 14 13 0.5 14 10 0.2
Prior gastrointestinal bleeding 8.2 7.3 0.5 13 7.1 0.01
Cognitive impairment or dementia 2.5 3.8 0.09 3.7 1.7 0.1
Frailty 5.2 4.1 0.3 8.2 2.7 0.007
BMI, kg/m
2 29 (26 to 34) 29 (26 to 35) 0.3 28 (25 to 33) 30 (26 to 36) 0.0002
Hemoglobin, g/dL 13.5 (12.3 to 14.6) 13.7 (12.6 to 14.8) 0.004 13.4 (12.1 to 14.5) 13.7 (12.5 to 14.9) 0.03
Calculated creatinine clearance*,
mL/min per 1.73 m
2
69 (50 to 94) 77 (55 to 101) <0.0001 69 (48 to 99) 77 (59 to 107) 0.003
Values are presented as % or median (IQR). BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; OAC, oral anticoagulant.
*As calculated by the Cockcroft-Gault formula.
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conservatism in new drug adoption respectful of the years of
experience with warfarin and the signiﬁcant toxicity that
emerged in postmarketing surveillance with the previous
generation of oral, direct-thrombin inhibitors.
15,16
Initial descriptions of dabigatran uptake from administra-
tive data in Denmark are consistent with ours. Sorensen et al
demonstrated modest early use of dabigatran in patients with
AF (5%), as well as signiﬁcant deviations from recommended
dosing practices.
17 Furthermore, they demonstrated the
preferred use of dabigatran in younger patients, with less
comorbidity. The risk-treatment paradox observed in our
study and the Danish population highlights the reticence of
providers to expose patients to the potential risk of a new
anticoagulant, despite proved safety and efﬁcacy. Of note,
outcomes in Danish patients receiving dabigatran compared
favorably with those of matched controls receiving warfarin.
18
Older patients with AF represent a signiﬁcant challenge in
the management of stroke prevention, as the risks of both
ischemic stroke and major hemorrhage (including intracranial
hemorrhage) are increased.
19–22 One strategy proposed to
mitigate this risk treatment paradox is the use of modiﬁed
dosing of novel anticoagulants in older patients. Guidelines in
both Canada and Europe suggest the use of the 110-mg dose
of dabigatran for older individuals (≥80 years), even in the
absence of renal dysfunction. In the United States, the Food
and Drug Administration did not approve this dose, as it found
no patient subgroup in which the beneﬁt outweighed the
risk.
4,7 However, a 75-mg twice-daily dose was approved for
individuals with severe renal impairment (CrCl 15 to 30 mL/
Table 5. Cardiovascular History
Use of Warfarin at Baseline No OAC at Baseline
Not Switched to
Dabigatran (n=6122)
Switched to
Dabigatran (n=532) P Value
Not Switched to
Dabigatran (n=1956)
Switched to
Dabigatran (n=184)
P
Value
Peripheral vascular disease 14 10.0 0.01 13 14 0.6
Coronary artery disease 34 22 <0.0001 33 26 0.03
Prior MI 17 8.5 <0.0001 18 13 0.08
Prior CABG 16 9.6 0.0001 15 10 0.1
Prior PCI 18 12 0.001 18 16 0.4
Heart Failure 35 26 <0.0001 27 18 0.01
Implanted cardiac device 30 22 0.0002 25 17 0.02
Significant valve disease 29 19 <0.0001 20 16 0.2
Moderate/severe mitral stenosis 1.9 0.6 0.03 0.7 0.5 0.8
Prior valve replacement 10.3 4.1 <0.0001 5.0 1.1 0.02
Mechanical Valve 4.4 0.6 <0.0001 1.0 0 0.2
Prior cerebrovascular events 17 14 0.06 13 9.2 0.1
Stroke (all cause) 9.7 7.9 0.2 7.0 4.9 0.3
Stroke—nonhemorrhagic 9.0 7.3 0.2 5.6 3.8 0.3
Stroke—hemorrhagic 0.6 0.6 0.98 1.3 1.1 0.8
Other intracranial bleeding 0.6 0.9 0.4 1.8 1.6 0.8
TIA 9.2 7.9 0.3 5.7 3.3 0.2
Cardiac medications
b-Blocker 67 61 0.006 58 62 0.2
Nondihydropyridine calcium
channel blocker
17 21 0.053 14 16 0.5
ACEI or ARB 54 56 0.2 45 41 0.3
Statin 57 55 0.3 51 52 0.8
LVEF, % 55 (50 to 60) 57 (50 to 64) 0.003 60 (53 to 64) 59 (53 to 65) 0.7
LA diameter, cm 4.5 (4.0 to 5.1) 4.5 (3.9 to 5.0) 0.09 4.2 (3.7 to 4.7) 4.3 (3.9 to 4.9) 0.09
Values are presented as % or median (interquartile range). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft
surgery; LA, left atrium; LVEF, left ventricular ejection fraction; MI, myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
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2). Our data demonstrate that for 14% of
patients aged ≥80 years (with preserved renal function),
physicians are opting for the 75-mg twice-daily dose, possibly
to offset bleeding risk. However, the sequelae of this dosing
strategy are unknown. Notably, the prescribing information for
the newest anticoagulant, apixaban, provides alternative
Table 6. Atrial Fibrillation and Anticoagulation History
Use of Warfarin at Baseline No OAC at Baseline
Not Switched to
Dabigatran (n=6122)
Switched to
Dabigatran (n=532) P Value
Not Switched to
Dabigatran (n=1956)
Switched to
Dabigatran (n=184) P Value
AF type at baseline
New onset 3.0 5.1 0.04 6.1 10 0.003
Paroxysmal 46 48 66 53
Persistent 18 17 13 16
Longstanding persistent 33 30 14 20
Time from AF diagnosis >12 mo 85 78 <0.0001 78 76 0.5
Rhythm control treatment strategy
reported
28 32 0.04 41 46 0.2
CHADS2 score, mean (SD) 2.4 (1.3) 2.1 (1.2) <0.0001 2.0 (1.4) 1.8 (1.1) 0.02
CHADS2 score groups
0 4.3 5.6 <0.0001 13 11 0.2
11 9 2 9 2 6 3 4
≥27 7 6 5 6 1 5 4
ATRIA Score, mean (SD) 2.8 (1.9) 2.5 (1.8) 0.0001 2.8 (2.1) 2.5 (1.9) 0.3
Prior cardioversion 32 35 0.2 22 30 0.02
Prior catheter ablation for AF 5.0 7.7 0.006 5.7 7.6 0.3
Prior antiarrhythmic therapy 44 51 0.004 48 54 0.1
Current antiarrhythmic therapy 26 31 0.01 35 43 0.03
Amiodarone 10.0 8.1 0.2 11 6.5 0.08
Dronedarone 3.8 7.0 0.0004 5.8 8.7 0.1
Sotalol 5.3 7.5 0.03 7.4 9.2 0.4
Flecainide 2.1 2.4 0.6 5.0 5.4 0.8
Propafenone 1.9 2.1 0.7 3.8 7.1 0.03
Dofetilide 1.9 3.0 0.08 1.8 1.6 0.8
Baseline antiplatelet therapy
Aspirin 36 37 0.6 74 67 0.046
Clopidogrel 4.8 3.6 0.2 16 10 0.04
Anticoagulation clinic management at
baseline
45 36 <0.0001 —— —
Relative or absolute contraindication
to anticoagulation
4.7 3.4 0.2 40 26 0.0001
Treating provider specialty*
Primary care provider 69 66 0.1 65 71 0.1
Cardiologist 81 82 0.6 77 82 0.1
Electrophysiologist 17 19 0.3 16 16 0.9
Neurologist 2.5 1.7 0.2 1.2 0 0.1
Values are presented as %, unless noted otherwise. AF indicates atrial ﬁbrillation; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CHADS2, estimated risk based on the
presence of congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack; OAC, oral anticoagulation.
*Provider specialty is not mutually exclusive; each patient may have ≥1 specialists involved in the care of AF patients.
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function impairment), based on the Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial Fibrillation
(ARISTOTLE) trial.
23,24 While preliminary data on dabigatran
have failed to show a signiﬁcant increased risk of bleeding
with the US dosing regimen,
14 more detailed correlations
among dose, age, and outcomes are needed to guide
management.
Limitations
These data are derived from an observational cohort of
patients in clinical practice participating in a voluntary registry
and thus subject to the limitations inherent of such methods.
Speciﬁcally, sampling and/or reporting bias may inﬂuence the
results of dabigatran uptake. Data were acquired via chart
review, and their accuracy is therefore dependent on
completeness of initial documentation and thoroughness of
subsequent abstraction. Additionally, factors associated with
adoption of dabigatran cannot be interpreted as causal
relationships for switching therapies, and residual measured
and unmeasured confounding may account for some or all of
these ﬁndings. Similarly, precise timing of dabigatran initia-
tion, relative to interim events such as hospitalization, cannot
be precisely ascertained; this also limits any causal inferences
that can be made from these data. Last, the collection period
of the registry overlapped with the approval of dabigatran in
October 2010, thus capturing an early phase of adoption
following approval. This could have a signiﬁcant impact on the
rate of uptake observed in our study.
Conclusions
A modest number of US patients with AF have adopted the
use of dabigatran. A signiﬁcant proportion of these transitions
appear to be driven by the patients. Patients receiving
dabigatran were younger, had less comorbidity, and were at
lower risk of stroke and bleeding compared with those not
treated with dabigatran. They are often prescribed doses of
dabigatran that are not consistent with their renal function.
These ﬁndings of modest update of dabigatran coupled with
selection of lower-risk AF patients suggest that there has
been an initially conservative approach to the use of this new
therapy in clinical practice.
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